Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

RSSS US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

RSSS US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Research Solutions, Inc.(RSSS US)

$2.12+0.2312.17%Ext:$1.96-0.167.49%(Market Closed · 00:56:31 UTC)
Ask AI
ProfileEntity StructureAll DocumentsFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Research Solutions, Inc.(RSSS US)

$2.12+0.2312.17%Ext:$1.96-0.167.49%(Market Closed · 00:56:31 UTC)
Ask AI
ProfileEntity StructureAll DocumentsFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
All Documents

Financials & Metrics

FinancialsChartingShort InterestEmployees
All Documents

Financials & Metrics

FinancialsChartingShort InterestEmployees

Research Solutions, Inc. — Company Profile

Research Solutions, Inc., through its subsidiaries, provides research cloud-based software-as-a-service software platform and related services to corporate, academic, government and individual researchers in the United States, Europe, and internationally. It provides Discover Tools that facilitates search discovery across virtually all scientific, technical, and medical (STM) articles available, including basic search solutions and advanced search tools comprising Resolute.ai and Scite.ai products, a tools that allows for searching and identifying relevant research and find insights in other datasets adjacent to STM content, such as clinical trial, patent, life science and medtech regulatory information, competitor and technology landscape insights in addition to searching the customer’s internal datasets. The company also offers Article Galaxy and Article Galaxy Scholar, a solution that allows research organizations to load entitlements, including subscriptions, discount, or token packages, and existing library of articles. In addition, it provides Generative AI, a solution to help researchers understand the quality of the articles they are reviewing, speed up the review process, and to understand how various research papers relate to each other. Further, the company offers references solution, enables researchers to organize literature, collaborate with team members, and access collection of scientific content. Additionally, its platform facilitates the sale of published STM content sold as individual articles. The company was formerly known as Derycz Scientific, Inc. and changed its name to Research Solutions, Inc. in March 2013. Research Solutions, Inc. was incorporated in 2006 and is based in Henderson, Nevada.

Sector
Industrials
Industry
Transportation Infrastructure
Exchange
UQ
CEO
Roy W. Olivier
Headquarters
Henderson, NV, US
IPO Date
Nov 15, 2010
Employees
141
Website
www.researchsolutions.com

Key Metrics

Price
$2.15
Market Cap
$71.91M
Revenue (TTM)
$12.12M
Net Income (TTM)
$860.21K
EPS (TTM)
0.03
P/E (TTM)
25.48
P/B (TTM)
3.47
Dividend Yield
0.00%
ROE (TTM)
4.51%

Research Solutions, Inc. — Company Profile

Research Solutions, Inc., through its subsidiaries, provides research cloud-based software-as-a-service software platform and related services to corporate, academic, government and individual researchers in the United States, Europe, and internationally. It provides Discover Tools that facilitates search discovery across virtually all scientific, technical, and medical (STM) articles available, including basic search solutions and advanced search tools comprising Resolute.ai and Scite.ai products, a tools that allows for searching and identifying relevant research and find insights in other datasets adjacent to STM content, such as clinical trial, patent, life science and medtech regulatory information, competitor and technology landscape insights in addition to searching the customer’s internal datasets. The company also offers Article Galaxy and Article Galaxy Scholar, a solution that allows research organizations to load entitlements, including subscriptions, discount, or token packages, and existing library of articles. In addition, it provides Generative AI, a solution to help researchers understand the quality of the articles they are reviewing, speed up the review process, and to understand how various research papers relate to each other. Further, the company offers references solution, enables researchers to organize literature, collaborate with team members, and access collection of scientific content. Additionally, its platform facilitates the sale of published STM content sold as individual articles. The company was formerly known as Derycz Scientific, Inc. and changed its name to Research Solutions, Inc. in March 2013. Research Solutions, Inc. was incorporated in 2006 and is based in Henderson, Nevada.

Sector
Industrials
Industry
Transportation Infrastructure
Exchange
UQ
CEO
Roy W. Olivier
Headquarters
Henderson, NV, US
IPO Date
Nov 15, 2010
Employees
141
Website
www.researchsolutions.com

Key Metrics

Price
$2.15
Market Cap
$71.91M
Revenue (TTM)
$12.12M
Net Income (TTM)
$860.21K
EPS (TTM)
0.03
P/E (TTM)
25.48
P/B (TTM)
3.47
Dividend Yield
0.00%
ROE (TTM)
4.51%
ROA (TTM)
1.87%
Operating Margin
8.72%
Beta
0.44

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Research Solutions, Inc., through its subsidiaries, provides research cloud-based software-as-a-service software platform and related services to corporate, academic, government and individual researchers in the United States, Europe, and internationally. It provides Discover Tools that facilitates search discovery across virtually all scientific, technical, and medical (STM) articles available, including basic search solutions and advanced search tools comprising Resolute.ai and Scite.ai products, a tools that allows for searching and identifying relevant research and find insights in other datasets adjacent to STM content, such as clinical trial, patent, life science and medtech regulatory information, competitor and technology landscape insights in addition to searching the customer’s internal datasets. The company also offers Article Galaxy and Article Galaxy Scholar, a solution that allows research organizations to load entitlements, including subscriptions, discount, or token packages, and existing library of articles. In addition, it provides Generative AI, a solution to help researchers understand the quality of the articles they are reviewing, speed up the review process, and to understand how various research papers relate to each other. Further, the company offers references solution, enables researchers to organize literature, collaborate with team members, and access collection of scientific content. Additionally, its platform facilitates the sale of published STM content sold as individual articles. The company was formerly known as Derycz Scientific, Inc. and changed its name to Research Solutions, Inc. in March 2013. Research Solutions, Inc. was incorporated in 2006 and is based in Henderson, Nevada.

Website
www.researchsolutions.com
Location
Henderson, NV, US
Phone310 477 0354
Employees141
CEORoy W. Olivier
Sector
Industrials
Industry
Transportation Infrastructure
IPO DateNov 15, 2010

Latest Documents

SEC Filings(919)

Expand
  • ARSAnnual report to security holders1 Oct
  • DEFA14ADefinitive additional materials1 Oct
  • DEF 14ADefinitive proxy statement1 Oct
  • 10-KFY 2026ended 30 Jun 202611 Sep
  • 8-KResults of Operations and Financial Condition9 Sep
  • Form 4Cohen Sefton3 Aug
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers3 Aug
  • 10-QQ3ended 31 Mar 202615 May
  • 8-KResults of Operations and Financial Condition14 May
  • SC 13G/AResearch Solutions, Inc.11 May
  • Form 4Cohen Sefton6 May
  • 10-QQ2ended 31 Dec 202513 Feb
  • 8-KResults of Operations and Financial Condition12 Feb
  • Form 4Kutil David22 Dec 2025
  • Form 3Kutil David22 Dec 2025
  • Form 4Gayron Kenneth L16 Dec 2025
  • Form 4MCPEAK MERRILL A12 Dec 2025
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers11 Dec 2025
  • Form 4Regazzi John J21 Nov 2025
  • Form 4Regazzi John J21 Nov 2025

News

  • Research Solutions, Inc. (RSSS) Q1 2027 Earnings Call Transcript04:23PM
  • What Research Solutions (RSSS) Said on Its Q1 Earnings Call11:18AM
  • Research Solutions Inc. (RSSS) Q1 Earnings Beat Estimates16 Nov
  • Research Solutions Reports First Quarter Fiscal Year 2027 Results16 Nov
  • Research Solutions Announces Date and Time Change of First Quarter Fiscal Year 2027 Results and Conference Call11 Nov
  • Research Solutions Announces Agreement With Fortune 500 Biopharma Company Valued at $1 Million11 Nov
  • Research Solutions (RSSS) Expected to Release Quarterly Earnings on Thursday11 Nov
  • Research Solutions to Announce First Quarter Fiscal Year 2027 Results on Thursday, November 12, 20265 Nov
  • Research Solutions Brings Scite & Article Galaxy To Microsoft Copilot3 Nov
  • Research Solutions' Scite & MDPI Collaborate to Make Open Access Research Discoverable, Attributed, & Measurable Inside AI Tools6 Oct
  • Analyzing Charles River Associates (NASDAQ:CRAI) and Research Solutions (NASDAQ:RSSS)5 Oct
  • Research Solutions Launches Article Galaxy Plugin In The ChatGPT Plugin Directory, Bringing Rights-Cleared Article Access To AI Research Workflows16 Sep
  • Research Solutions, Inc. (RSSS) Q4 2026 Earnings Call Transcript9 Sep
  • Research Solutions Inc. (RSSS) Misses Q4 Earnings Estimates9 Sep
  • Research Solutions Q4 Earnings Call Highlights9 Sep
  • Research Solutions Reports Fourth Quarter and Fiscal Year 2026 Results9 Sep
  • Research Solutions to Announce Fourth Quarter and Fiscal Year 2026 Results on Wednesday, September 9, 20261 Sep
  • Research Solutions to Announce Fourth Quarter and Fiscal Year 2026 Results on Wednesday, September 9, 20261 Sep
  • Research Solutions Targets AI-Driven Growth as High-Margin SaaS Revenue Rises29 Aug
  • Research Solutions to Participate at Upcoming Investor Conferences18 Aug

Mentions in Filings

  • … y. Combined with our continued focus on operational excellence, we are confident in our ability to deliver sustained, above-market growth and long-term shareholder value. " During the event, Revvity will highlight three key areas: •A differentiated portfolio: Strong positions across attractive Life Sciences and Diagnostics markets, supported by innovative <strong>research solutions</strong>, specialized diagnostic technologies and leading software capabilities.
    REVVITY, INC.Research Solutions, Inc.·EX-99.1 - 8-K - Regulation FD Disclosure·Q4 26·13 Nov
  • … perations, including development of our iPSC cell therapy platforms, product characterization, and process analytics from the time product candidates are in early research phases. Our investments also include scaled <strong>research solutions</strong>, scaled infrastructure, and novel technologies intended to improve efficiency, characterization, and scalability of manufacturing. We anticipate that we will need to raise additional financing in the future to fund …
    Century Therapeutics, Inc.Research Solutions, Inc.·10-Q - Quarterly report Q3·Q3 26·12 Nov
  • … consideration to be paid in cash based on the achievement of certain revenue metrics over a two-year period. HCD is a biotechnology company based in Toulouse, France specializing in human cell models and preclinical <strong>research solutions</strong> for diabetes, obesity and other metabolic diseases. The transaction is expected to close in the fourth quarter of fiscal year 2026 and is subject to customary closing conditions, including required regulatory approv …
    REVVITY, INC.Research Solutions, Inc.·10-Q - Quarterly report Q3·Q3 26·10 Nov
  • … til July 2023. From January 2020 until December 2023, Dr. Margolin served as the Chief Medical Officer of Eikonizo Therapeutics, Inc., a biotechnology company, and he is the Founder and Principal Consultant of CNS <strong>Research Solutions</strong> LLC, a consulting firm supporting the development of novel therapeutics for CNS disorders since May 2018. From December 2016 to April 2018, Dr. Margolin served as Executive Director, Internal Medicine Research Uni …
    REVIVA PHARMACEUTICALS HOLDINGS, INC.Research Solutions, Inc.·ARS - Annual report to security holders·FY25·9 Nov
  • … until July 2023. From January 2020 until December 2023, Dr. Margolin served as the Chief Medical Officer of Eikonizo Therapeutics, Inc., a biotechnology company, and he is the Founder and Principal Consultant of CNS <strong>Research Solutions</strong> LLC, a consulting firm supporting the development of novel therapeutics for CNS disorders since May 2018. From December 2016 to April 2018, Dr. Margolin served as Executive Director, Internal Medicine Research Unit …
    REVIVA PHARMACEUTICALS HOLDINGS, INC.Research Solutions, Inc.·DEF 14A - Definitive proxy statement·Q4 26·9 Nov
  • … oned not to unduly rely upon these statements. Overview We are a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biology. Our integrated <strong>research solutions</strong> consist of instruments, consumables and software across our Single Cell and Spatial portfolios. Our instruments include our Chromium instruments for Single Cell and our Visium CytAssist, Xenium Analyzer and Atera in …
    10x Genomics, Inc.Research Solutions, Inc.·10-Q - Quarterly report Q3·Q3 26·5 Nov

Key Stats

Trading

Px/Chg 1D$2.15 / +0.94%
Avg Volume73.89K
Beta0.44
Mkt Cap71.91M
FD Mkt Cap73.58M

Float

Shrs Out/Float33.45M / 25.17M
Short Float0.00%
Days to Cover2.07
Stock Repurchased$7.84K

Current Valuation

EV59.28M
EV/EBITDA13.13
EV/Sales1.23
P/B3.47
P/S1.49
FCF Yield7.28%
ROE4.51%
ROA1.87%
Current Ratio0.82

Estimates

P/E25.48
Est P/E0.00
Est EPS0.04
Est PEG0.00

Valuation

Metric5Yr AvgNov '22Nov '23Nov '24Nov '25Oct '26
PRICE-BASED RATIOS
Price / Earnings25.07-33.02111.37-21.2742.8025.48
Price / Sales2.951.641.691.808.121.49
Price / Book Value7.4711.048.686.897.253.47
Price / Free Cash Flow-3.19-116.8019.0823.1444.8713.74
ENTERPRISE VALUE METRICS
Enterprise Value63.243.350.174.488.859.3
Enterprise Value / Sales2.541.311.331.677.141.23
Enterprise Value / EBITDA232.94-29.45296.00844.6233.0920.42
Enterprise Value / EBIT67.70-29.10429.60-99.4937.490.00

Financials

Full Financials
Millions USD5Yr CAGR (%)Jun '22Jun '23Jun '24Jun '25Jun '26
INCOME STATEMENT
Revenue10.1%32.937.744.649.148.3
Gross Income20.2%12.014.719.624.225.1
EBITDA—-1.50.20.13.52.9
EBIT—-1.50.1-0.72.3-
Net Income—-1.60.6-3.81.32.8
EPS (Diluted)—-0.060.02-0.130.040.09
BALANCE SHEET
Cash & ST Inv4.5%10.613.56.112.212.6
Total Assets28%17.021.841.946.145.7
Total Liabilities19.7%12.114.530.232.225.0
Total Shareholder Equity43.5%4.97.311.713.920.7
CASH FLOW
Net Operating Cash Flow—-0.43.43.67.05.3
Cap Ex-2.7%-0.0-0.0-0.1-0.0-0.0
Free Cash Flow—-0.53.33.57.05.2

Enterprise Value Bridge

Millions USD17 Nov '26
Price (As of 17 Nov '26)2.10
Basic Shares33.45
Market Cap70.2
Diluted Shares31.79
Fully Diluted Shares Outstanding31.79
Fully Diluted Market Cap66.8
+Consolidated Debt-
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-12.6
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value57.6

Segment data

Revenue

by Products and services

  • Transactions57%
  • Platforms43%

Revenue

by Geography

  • Europe100%

Related companies

Visa Inc.

V US

Mastercard Inc

MA US

Alibaba Group Holding Ltd

BABA US

Delta Electronics, Inc.

2308 TT

Uber Technologies, Inc

UBER US

Keyence Corporation

KYCCF US

Accenture Public Limited Company

ACN US

Hon Hai Precision Industry Co., Ltd.

HNHPF US

Murata Manufacturing Co., Ltd.

MRAAY US

Venture Corporation Limited

VEMLY US

DoorDash, Inc.

DASH US

Unimicron Technology Corp.

3037 TT

ROA (TTM)
1.87%
Operating Margin
8.72%
Beta
0.44

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Research Solutions, Inc., through its subsidiaries, provides research cloud-based software-as-a-service software platform and related services to corporate, academic, government and individual researchers in the United States, Europe, and internationally. It provides Discover Tools that facilitates search discovery across virtually all scientific, technical, and medical (STM) articles available, including basic search solutions and advanced search tools comprising Resolute.ai and Scite.ai products, a tools that allows for searching and identifying relevant research and find insights in other datasets adjacent to STM content, such as clinical trial, patent, life science and medtech regulatory information, competitor and technology landscape insights in addition to searching the customer’s internal datasets. The company also offers Article Galaxy and Article Galaxy Scholar, a solution that allows research organizations to load entitlements, including subscriptions, discount, or token packages, and existing library of articles. In addition, it provides Generative AI, a solution to help researchers understand the quality of the articles they are reviewing, speed up the review process, and to understand how various research papers relate to each other. Further, the company offers references solution, enables researchers to organize literature, collaborate with team members, and access collection of scientific content. Additionally, its platform facilitates the sale of published STM content sold as individual articles. The company was formerly known as Derycz Scientific, Inc. and changed its name to Research Solutions, Inc. in March 2013. Research Solutions, Inc. was incorporated in 2006 and is based in Henderson, Nevada.

Website
www.researchsolutions.com
Location
Henderson, NV, US
Phone310 477 0354
Employees141
CEORoy W. Olivier
Sector
Industrials
Industry
Transportation Infrastructure
IPO DateNov 15, 2010

Latest Documents

SEC Filings(919)

Expand
  • ARSAnnual report to security holders1 Oct
  • DEFA14ADefinitive additional materials1 Oct
  • DEF 14ADefinitive proxy statement1 Oct
  • 10-KFY 2026ended 30 Jun 202611 Sep
  • 8-KResults of Operations and Financial Condition9 Sep
  • Form 4Cohen Sefton3 Aug
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers3 Aug
  • 10-QQ3ended 31 Mar 202615 May
  • 8-KResults of Operations and Financial Condition14 May
  • SC 13G/AResearch Solutions, Inc.11 May
  • Form 4Cohen Sefton6 May
  • 10-QQ2ended 31 Dec 202513 Feb
  • 8-KResults of Operations and Financial Condition12 Feb
  • Form 4Kutil David22 Dec 2025
  • Form 3Kutil David22 Dec 2025
  • Form 4Gayron Kenneth L16 Dec 2025
  • Form 4MCPEAK MERRILL A12 Dec 2025
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers11 Dec 2025
  • Form 4Regazzi John J21 Nov 2025
  • Form 4Regazzi John J21 Nov 2025

News

  • Research Solutions, Inc. (RSSS) Q1 2027 Earnings Call Transcript04:23PM
  • What Research Solutions (RSSS) Said on Its Q1 Earnings Call11:18AM
  • Research Solutions Inc. (RSSS) Q1 Earnings Beat Estimates16 Nov
  • Research Solutions Reports First Quarter Fiscal Year 2027 Results16 Nov
  • Research Solutions Announces Date and Time Change of First Quarter Fiscal Year 2027 Results and Conference Call11 Nov
  • Research Solutions Announces Agreement With Fortune 500 Biopharma Company Valued at $1 Million11 Nov
  • Research Solutions (RSSS) Expected to Release Quarterly Earnings on Thursday11 Nov
  • Research Solutions to Announce First Quarter Fiscal Year 2027 Results on Thursday, November 12, 20265 Nov
  • Research Solutions Brings Scite & Article Galaxy To Microsoft Copilot3 Nov
  • Research Solutions' Scite & MDPI Collaborate to Make Open Access Research Discoverable, Attributed, & Measurable Inside AI Tools6 Oct
  • Analyzing Charles River Associates (NASDAQ:CRAI) and Research Solutions (NASDAQ:RSSS)5 Oct
  • Research Solutions Launches Article Galaxy Plugin In The ChatGPT Plugin Directory, Bringing Rights-Cleared Article Access To AI Research Workflows16 Sep
  • Research Solutions, Inc. (RSSS) Q4 2026 Earnings Call Transcript9 Sep
  • Research Solutions Inc. (RSSS) Misses Q4 Earnings Estimates9 Sep
  • Research Solutions Q4 Earnings Call Highlights9 Sep
  • Research Solutions Reports Fourth Quarter and Fiscal Year 2026 Results9 Sep
  • Research Solutions to Announce Fourth Quarter and Fiscal Year 2026 Results on Wednesday, September 9, 20261 Sep
  • Research Solutions to Announce Fourth Quarter and Fiscal Year 2026 Results on Wednesday, September 9, 20261 Sep
  • Research Solutions Targets AI-Driven Growth as High-Margin SaaS Revenue Rises29 Aug
  • Research Solutions to Participate at Upcoming Investor Conferences18 Aug

Mentions in Filings

  • … y. Combined with our continued focus on operational excellence, we are confident in our ability to deliver sustained, above-market growth and long-term shareholder value. " During the event, Revvity will highlight three key areas: •A differentiated portfolio: Strong positions across attractive Life Sciences and Diagnostics markets, supported by innovative <strong>research solutions</strong>, specialized diagnostic technologies and leading software capabilities.
    REVVITY, INC.Research Solutions, Inc.·EX-99.1 - 8-K - Regulation FD Disclosure·Q4 26·13 Nov
  • … perations, including development of our iPSC cell therapy platforms, product characterization, and process analytics from the time product candidates are in early research phases. Our investments also include scaled <strong>research solutions</strong>, scaled infrastructure, and novel technologies intended to improve efficiency, characterization, and scalability of manufacturing. We anticipate that we will need to raise additional financing in the future to fund …
    Century Therapeutics, Inc.Research Solutions, Inc.·10-Q - Quarterly report Q3·Q3 26·12 Nov
  • … consideration to be paid in cash based on the achievement of certain revenue metrics over a two-year period. HCD is a biotechnology company based in Toulouse, France specializing in human cell models and preclinical <strong>research solutions</strong> for diabetes, obesity and other metabolic diseases. The transaction is expected to close in the fourth quarter of fiscal year 2026 and is subject to customary closing conditions, including required regulatory approv …
    REVVITY, INC.Research Solutions, Inc.·10-Q - Quarterly report Q3·Q3 26·10 Nov
  • … til July 2023. From January 2020 until December 2023, Dr. Margolin served as the Chief Medical Officer of Eikonizo Therapeutics, Inc., a biotechnology company, and he is the Founder and Principal Consultant of CNS <strong>Research Solutions</strong> LLC, a consulting firm supporting the development of novel therapeutics for CNS disorders since May 2018. From December 2016 to April 2018, Dr. Margolin served as Executive Director, Internal Medicine Research Uni …
    REVIVA PHARMACEUTICALS HOLDINGS, INC.Research Solutions, Inc.·ARS - Annual report to security holders·FY25·9 Nov
  • … until July 2023. From January 2020 until December 2023, Dr. Margolin served as the Chief Medical Officer of Eikonizo Therapeutics, Inc., a biotechnology company, and he is the Founder and Principal Consultant of CNS <strong>Research Solutions</strong> LLC, a consulting firm supporting the development of novel therapeutics for CNS disorders since May 2018. From December 2016 to April 2018, Dr. Margolin served as Executive Director, Internal Medicine Research Unit …
    REVIVA PHARMACEUTICALS HOLDINGS, INC.Research Solutions, Inc.·DEF 14A - Definitive proxy statement·Q4 26·9 Nov
  • … oned not to unduly rely upon these statements. Overview We are a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biology. Our integrated <strong>research solutions</strong> consist of instruments, consumables and software across our Single Cell and Spatial portfolios. Our instruments include our Chromium instruments for Single Cell and our Visium CytAssist, Xenium Analyzer and Atera in …
    10x Genomics, Inc.Research Solutions, Inc.·10-Q - Quarterly report Q3·Q3 26·5 Nov

Key Stats

Trading

Px/Chg 1D$2.15 / +0.94%
Avg Volume73.89K
Beta0.44
Mkt Cap71.91M
FD Mkt Cap73.58M

Float

Shrs Out/Float33.45M / 25.17M
Short Float0.00%
Days to Cover2.07
Stock Repurchased$7.84K

Current Valuation

EV59.28M
EV/EBITDA13.13
EV/Sales1.23
P/B3.47
P/S1.49
FCF Yield7.28%
ROE4.51%
ROA1.87%
Current Ratio0.82

Estimates

P/E25.48
Est P/E0.00
Est EPS0.04
Est PEG0.00

Valuation

Metric5Yr AvgNov '22Nov '23Nov '24Nov '25Oct '26
PRICE-BASED RATIOS
Price / Earnings25.07-33.02111.37-21.2742.8025.48
Price / Sales2.951.641.691.808.121.49
Price / Book Value7.4711.048.686.897.253.47
Price / Free Cash Flow-3.19-116.8019.0823.1444.8713.74
ENTERPRISE VALUE METRICS
Enterprise Value63.243.350.174.488.859.3
Enterprise Value / Sales2.541.311.331.677.141.23
Enterprise Value / EBITDA232.94-29.45296.00844.6233.0920.42
Enterprise Value / EBIT67.70-29.10429.60-99.4937.490.00

Financials

Full Financials
Millions USD5Yr CAGR (%)Jun '22Jun '23Jun '24Jun '25Jun '26
INCOME STATEMENT
Revenue10.1%32.937.744.649.148.3
Gross Income20.2%12.014.719.624.225.1
EBITDA—-1.50.20.13.52.9
EBIT—-1.50.1-0.72.3-
Net Income—-1.60.6-3.81.32.8
EPS (Diluted)—-0.060.02-0.130.040.09
BALANCE SHEET
Cash & ST Inv4.5%10.613.56.112.212.6
Total Assets28%17.021.841.946.145.7
Total Liabilities19.7%12.114.530.232.225.0
Total Shareholder Equity43.5%4.97.311.713.920.7
CASH FLOW
Net Operating Cash Flow—-0.43.43.67.05.3
Cap Ex-2.7%-0.0-0.0-0.1-0.0-0.0
Free Cash Flow—-0.53.33.57.05.2

Enterprise Value Bridge

Millions USD17 Nov '26
Price (As of 17 Nov '26)2.10
Basic Shares33.45
Market Cap70.2
Diluted Shares31.79
Fully Diluted Shares Outstanding31.79
Fully Diluted Market Cap66.8
+Consolidated Debt-
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-12.6
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value57.6

Segment data

Revenue

by Products and services

  • Transactions57%
  • Platforms43%

Revenue

by Geography

  • Europe100%

Related companies

Visa Inc.

V US

Mastercard Inc

MA US

Alibaba Group Holding Ltd

BABA US

Delta Electronics, Inc.

2308 TT

Uber Technologies, Inc

UBER US

Keyence Corporation

KYCCF US

Accenture Public Limited Company

ACN US

Hon Hai Precision Industry Co., Ltd.

HNHPF US

Murata Manufacturing Co., Ltd.

MRAAY US

Venture Corporation Limited

VEMLY US

DoorDash, Inc.

DASH US

Unimicron Technology Corp.

3037 TT